Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harry Chingon

Psychiatry Aiea, HI Medical Doctor

NPI 1942242854 CMS profile 314947

98-211 Pali Momi St, Ste 414, Aiea, HI 96701

Open in the dashboard

General payments

$15,327

908 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harry Chingon of Aiea, HI is reported in the CMS Open Payments database as having received $15,327 across 908 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,414 132
2024 General $2,658 127
2023 General $2,305 137
2022 General $2,297 161
2021 General $2,044 131
2020 General $1,989 121
2019 General $1,620 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harry Chingon
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Harry Chingon were reported at $2,414. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Harry Chingon Psychiatry median Middle half National median
2019 $1,620 $184 $59–$605 $163
2020 $1,989 $119 $36–$372 $114
2021 $2,044 $143 $43–$576 $132
2022 $2,297 $153 $50–$590 $149
2023 $2,305 $170 $56–$651 $160
2024 $2,658 $179 $57–$673 $164
2025 $2,414 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $2,499 139 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $2,451 192 payments
  3. ITI, Inc. $1,499 69 payments
  4. Otsuka America Pharmaceutical, Inc. $1,497 78 payments
  5. AbbVie, Inc. $1,442 80 payments
  6. Alkermes, Inc. $1,267 77 payments
  7. Lundbeck LLC $1,222 93 payments
  8. Neurocrine Biosciences, Inc. $774 35 payments
  9. Allergan Inc. $507 32 payments
  10. E.R. Squibb & Sons, L.L.C. $431 13 payments
  11. Other $1,738 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,327 908 payments
Products named General payments · program years 2019–2025
  1. LATUDA $2,499 139 payments
  2. TRINTELLIX $1,992 151 payments
  3. REXULTI Psychiatry $1,512 73 payments
  4. LYBALVI $1,267 77 payments
  5. ARISTADA Cns $1,247 76 payments
  6. ARISTADA Cns $1,247 76 payments
  7. VRAYLAR $1,164 66 payments
  8. CAPLYTA $1,163 54 payments
  9. REXULTI Psychiatry $998 70 payments
  10. ARISTADA Cns $991 59 payments
  11. Other $6,661 407 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

908 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record